Phar­ma vets with Genen­tech con­nec­tion band to­geth­er to launch new im­munother­a­py start­up, though de­tails are scant

On Thurs­day, three re­searchers an­nounced they had start­ed up a new im­munother­a­py biotech called LTZ Ther­a­peu­tics, short for “Lift To Zenith,” and launched with a mod­est raise they’re call­ing a “pre-Se­ries A.” In to­tal, it’s a $17 mil­lion round, led by K2 Ven­ture Part­ners and as­sist­ed by Qim­ing Ven­ture Part­ners and Tigermed.

There are few de­tails so far, but the com­pa­ny is mak­ing an ini­tial im­pres­sion thanks to a di­rect con­nec­tion to Genen­tech.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN